Turkey - Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape
Summary
GlobalData, the industry analysis specialist, has released its latest report “Turkey - Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Turkey. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
Owing to the size of the Turkish population and their growing health concerns, the Turkish healthcare sector is potentially attractive for multinational firms seeking to invest in joint ventures and other types of mutually beneficial collaborations with their Turkish counterparts. Turkey's favorable environment for pharmaceutical investments is driven by strong government support, manufacturing, and R&D incentives, increasing per capita income, an expanding middle-class population, among others. In terms of US dollars, the pharmaceutical market increased from $6.7 billion in 2015 to $7.4 billion in 2019, at a CAGR of 2.5%. The market is expected to grow further at a CAGR of 0.7% from 2021 to $7.8 billion in 2027. In terms of Turkish Liras, the country’s pharmaceutical market increased from TL18.3 billion in 2015 to TL42.1 billion in 2019 at a CAGR of 23.1%. The market is expected to grow further at a CAGR of 21.8% from 2021 to 2027, reaching TL203.7 billion in 2027. The Turkish medical device market was worth $5.1 billion in 2016, and it is expected to grow at a CAGR of 5.4% to $7.0 billion in 2021. It is predicted to expand at a CAGR of 3.2% during 2022-2027, reaching $7.9 billion in 2027. According to the Association of Research-Based Pharmaceutical Companies (Araştrmac laç Firmalar Dernei), the Turkish government is working towards boosting the R&D spending above 3% of GDP and growing the exports to $500 billion by 2023, transforming Turkey into one of the top ten nations in the world for healthcare.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Turkey, and includes -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook